Fiboflapon, 5-脂氧合酶活化蛋白抑制剂

纤维瓣

Fiboflapon

F656043-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

Fiboflapon (GSK2190915; AM-803) is a potent and orally bioavailable 5-lipoxygenase-activating protein ( FLAP ) inhibitor with a potency of 2.9 nM in FLAP binding, an IC 50 of 76 nM for inhibition of LTB4 in human blood In Vitro Fiboflapon (AM-803) exhibits excellent preclinical toxicology and pharmacokinetics in rat and dog. Fiboflapon (AM-803) also demonstrated an extended pharmacodynamic effect in a rodent bronchoalveolar lavage (BAL) model . MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Oral administration of Fiboflapon (AM-803: 1 mg/kg) results in sustained inhibition of ex vivo ionophore-challenged whole blood LTB4 biosynthesis with >90% inhibition for up to 12 h and an EC 50 of approximately 7 nM. When rat lungs are challenged in vivo with calcium-ionophore, Fiboflapon (AM-803) inhibits LTB4 and cysteinyl leukotriene (CysLT) production with ED 50 s of 0.12 mg/kg and 0.37 mg/kg, respectively. The inhibition measured 16 h following a single oral dose of 3 mg/kg was 86% and 41% for LTB4 and CysLTs, respectively. In an acute inflammation setting, Fiboflapon dose-dependently reduced LTB4, CysLTs, plasma protein extravasation and neutrophil influx induced by peritoneal zymosan injection. Finally, Fiboflapon increases survival time in mice exposed to a lethal intravenous injection of platelet activating factor (PAF) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. IC50& Target:LTB 4 76 nM (IC 50 )

Fiboflapon（GSK2190915；AM-803）是一种口服生物活性强的 5-脂氧合酶激活蛋白（FLAP）抑制剂，与 FLAP 结合的效力为 2.9 nM，抑制人体血液中 LTB4 的 IC 50 为 76 nM。

936350-00-4(DMSO)

C38H43N3O4S

637.83 g/mol

CC(C(O)=O)(C)CC1=C(SC(C)(C)C)C2=CC(OCC3=CC=C(C)C=N3)=CC=C2N1CC4=CC=C(C5=CN=C(OCC)C=C5)C=C4

抑制剂

5-脂氧合酶活化蛋白抑制剂